Tumor-targeted activatable molecular agent for synergistic chemo-photodynamic therapy

  • Bioorg Chem. 2026 Sep 15:180:110199. doi: 10.1016/j.bioorg.2026.110199.
Zhao Liu  1 Chunwei Mo  2 Jiaying Shi  2 Yucheng Fei  2 Youguang Zheng  2 Xiancun Hou  3 Gang Wang  4 Tonghui Huang  5
Affiliations
  • 1. Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou 221004, China; Department of Nuclear Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
  • 2. School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, China.
  • 3. Department of Nuclear Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. Electronic address: [email protected].
  • 4. Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou 221004, China. Electronic address: [email protected].
  • 5. School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, China. Electronic address: [email protected].
Abstract

The combination of photodynamic therapy (PDT) and chemotherapy offers a promising strategy to enhance Cancer treatment efficacy. Herein, we report the design and synthesis of TBBS-CPT, a tumor-targeted, unimolecular therapeutic agent that covalently integrates a camptothecin (CPT) chemotherapeutic motif and a Photosensitizer module via a glutathione (GSH)-cleavable disulfide linker, further modified with a biotin ligand for tumor targeting. In vitro characterization and cellular studies demonstrated that TBBS-CPT acts as an activatable prodrug, efficiently releasing both CPT and the Photosensitizer in response to intracellular GSH, thereby inducing a potent chemo-photodynamic synergistic cytotoxic effect against 4 T1 tumor cells. The conjugate exhibited selective accumulation in biotin receptor-positive tumor cells and preferential localization within mitochondria. In vivo studies further confirmed the tumor-specific accumulation of TBBS-CPT and its enhanced therapeutic efficacy through the combination of chemotherapy and PDT in 4 T1 tumor-bearing mice. Collectively, these findings highlight TBBS-CPT as a promising tumor-targeted activatable therapeutic agent capable of integrating controlled drug release and synergistic chemo-photodynamic therapy for precise Cancer treatment.

Keywords
Aggregation-induced emission; Chemo-photodynamic therapy; Prodrugs; Tumor targeting.
Products